ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2666

The Risk for Development of Myositis Is Not Increased After COVID-19 Vaccination Among U.S. Veterans
Abstract Number: 2667

Anti-Mi2 Autoantibodies in Dermatomyositis Patients Also Recognize Autoimmune Regulator (AIRE) Protein
Abstract Number: 2668

Do Levels of anti-Jo1 Autoantibodies Have a Prognostic Role? Longitudinal Assessment of anti-Jo1 and HisRS Protein Levels in a Cohort of anti-Jo1 Positive Patients with Anti-synthetase Syndrome
Abstract Number: 2669

Dysferlin Autoantibodies Compromise Sarcolemmal Repair Capacity and Contribute to the Pathogenesis of Idiopathic Immune Myopathies
Abstract Number: 2670

Sera from Patients with Idiopathic Inflammatory Myopathy Induces Muscle Weakness, Mitochondrial Dysfunction and Induction of Cytokines in Isolated Skeletal Muscle
Abstract Number: 2671

Subcutaneous Abatacept vs Adalimumab Head-to-Head Comparison in Adults with Early, Dual Seropositive Rheumatoid Arthritis, Positive for the Shared Epitope HLA Class II Risk Alleles, and an Inadequate Response to Methotrexate: Results from a Phase 3 Trial
Abstract Number: 2672

Prevention of the Development of Rheumatoid Arthritis by a 1-year Course of Methotrexate in ACPA-negative Arthralgia Patients at Increased Risk for Rheumatoid Arthritis: 4 Year Results of the TREAT EARLIER Trial
Abstract Number: 2673

Changes in Mortality Risk After Stopping Glucocorticosteroids – a Population-based Study in Rheumatoid Arthritis
Abstract Number: 2674

Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a 1st-Line Tumor Necrosis Factor Inhibitor in the United States
Abstract Number: 2675

Which Arthralgia Patients at Risk for RA Benefited from Treatment with Methotrexate?; Results from the TREAT EARLIER Trial
Abstract Number: 2676

Timeframe for Initiating Methotrexate and Vaccine Response Against Pneumococcus in Rheumatoid Arthritis: The VACIMRA Study
Abstract Number: 2677

N-Acetylcysteine Blocks the Mechanistic Target of Rapamycin in Pro-Inflammatory Effector-Memory CD4 and CD8 T Cells Re-Expressing CD45RA in Patients with Active Systemic Lupus Erythematosus
Abstract Number: 2678

History of Cutaneous Lupus Promotes Blood and Skin Interferon Signatures in SLE Patients
Abstract Number: 2679

Predictors of Fracture in SLE: A Longitudinal Cohort Study
Abstract Number: 2680

Thrombocytopenia in Patients with Systemic Lupus ErythematosusReal-World Data Based on a Nationwide Database, RISE

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].